reports
Ford Equity International Rating and Forecast Report
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Operations gradually get back on track; product launches drive growth
​In our view, the worst is over for ScinoPharm as its near-term operations are stable, while we expect strong growth momentum driven by product launches, with a rich pipeline in 2H16-2018. 1H16 net profit grew 41% YoY to NT$350 mn, and was largely in line, while 1H16 GM of 44% was significantly stronger vs. 36.5% in 1H15. We reiterate our BUY rating as 1) its near-term operations have stabilized, with GM improving; and 2) new product launches will provide strong momentum (leukemia drug Decitab...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.